Zuhal Uckun Sahinogullari

Dr. Zuhal Uckun Sahinogullari

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2009 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
HSH. Sinan Suzen
H. Sinan Suzen
EGEmel Gucyener
Emel Gucyener
OSOzgul Sakalli
Ozgul Sakalli
ZSZuhal Uckun Sahinogullari
Zuhal Uckun Sahinogullari
GKGulcin Kose
Gulcin Kose
YDYalcin Duydu
Yalcin Duydu

27 September 2018 in Drug and Chemical Toxicology
Verified
Journal Article
Closed access
ZSZuhal Uckun Sahinogullari
Zuhal Uckun Sahinogullari
SGSevda Guzel
Sevda Guzel
NCNecmiye Canacankatan
Necmiye Canacankatan
CYCem Yalaza
Cem Yalaza
DKDeniz Kibar
Deniz Kibar
BYBanu Coskun Yilmaz
Banu Coskun Yilmaz
Vancomycin (VCM), a glycopeptide antibiotic, is a drug widely used in severe infections. However, VCM induce notable nephrotoxic side effects. Naringenin (NAR) is a natural of flavonoid and are known as strongly antioxidant, nefroprotective, antiapoptotic, and anti-inflammatory. The purpose of this study was to determine the potential protective effects of NAR against VCM-induced nephrotoxicity by measuring apoptotic and oxidative stress markers and evaluating histopathological alterations in rats. For this purpose, we used male Wistar albino rats that divided into seven groups: (i) Control [saline, intraperitoneally (i.p.)], (ii) carboxymethyl cellulose (0.5% CMC, orally), (iii) VCM (400 mg/kg, i.p.), (iv) NAR100 (100 mg/kg, orally), (v) VCM + NAR25 (25 mg/kg, orally), (vi) VCM + NAR50 (50 mg/kg, orally), and (vii) VCM + NAR100 (100 mg/kg, orally) groups. VCM administration was started one day after the first treatment of NAR and continued across 7-day. Caspase-3, -8, and-9 activities and malondialdehyde (MDA) and nitric oxide (NO) levels were measured by colorimetric methods in the kidney tissues, creatinine, and blood urea nitrogen (BUN) levels were analyzed based on ELISA in serum. Caspase-3 and -8 activities, NO levels, serum creatinine and BUN levels were significantly higher in VCM group in comparison with VCM + NAR (25, 50, and 100) groups (p < 0.05). Caspase-9 activity and MDA were significantly higher in VCM group compared to VCM + NAR (25 and 50) groups (p < 0.05). Histopathological alterations in VCM group were significantly diminished by administration of NAR, especially NAR 25. In conclusion, NAR 25 and 50 mg have more potent protective effects on VCM-induced nephrotoxicity compared to NAR 100 mg.

30 June 2021 in Clinical and Experimental Health Sciences
Verified
Journal Article
Closed access
ZSZuhal Uckun Sahinogullari
Zuhal Uckun Sahinogullari
SGSevda Güzel
Sevda Güzel
NCNecmiye Canacankatan
Necmiye Canacankatan
CYCem Yalaza
Cem Yalaza
DKDeniz Ki̇bAr
Deniz Ki̇bAr
GBGulsen Bayrak
Gulsen Bayrak
Objective: This investigation aimed to detect the possible protective impacts of naringenin (NAR) on vancomycin (VCM)-induced liver toxicity through measuring caspase-3, -8 and -9 activities as markers of apoptosis and the levels of tumor necrosis factor-alpha, cyclooxygenase-2 and vascular endothelial growth factor as inflammation markers and assessing the histopathological alterations in rats. Methods: The rats were allocated into seven groups as, the control group (saline, intraperitoneally (i.p.)), VCM group (400 mg/kg/day, i.p.), Carboxymethyl cellulose group (0.5% CMC, orally), NAR100 group (100 mg/kg/day, orally), VCM+NAR25 group (25 mg/kg/day, orally), VCM+NAR50 group (50 mg/kg/day, orally), VCM+NAR100 group (100 mg/kg/day, orally). The caspase enzyme activities and inflammation markers were measured using colorimetric methods and ELISA, respectively. Histopathological examinations were performed. Results: The caspase activities and levels of inflammation markers were significantly higher in the VCM group as opposed to the other groups. The caspase activities were significantly ameliorated in the VCM+NAR25 group compared to the VCM+NAR50 and VCM+NAR100 groups, but the levels of inflammation markers were significantly attenuated in VCM+NAR50 group and, especially, VCM+NAR100 group compared to VCM+NAR25 group. Conclusion: NAR has potential protective impact on liver injury caused by VCM, and the protective impacts of NAR at distinct doses may occur via different molecular mechanisms.

31 December 2020 in İstanbul Journal of Pharmacy
Verified
Journal Article
Open access
PDF file
ZSZuhal Uckun Sahinogullari
Zuhal Uckun Sahinogullari
İstanbul Üniversitesi Yayın Projesi

1 January 2016 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
ZSZuhal Uckun Sahinogullari
Zuhal Uckun Sahinogullari
BBBora Başkak
Bora Başkak
HÖHatice Özdemir
Hatice Özdemir
EOErguvan Tugba Ozel-Kizil
Erguvan Tugba Ozel-Kizil
HOHalise Devrimci Ozguven
Halise Devrimci Ozguven
HSHalit Sinan Süzen
Halit Sinan Süzen

25 March 2021 in Journal of Contemporary Medicine
Verified
Journal Article
Closed access
PDF file
ZSZuhal Uckun Sahinogullari
Zuhal Uckun Sahinogullari
Aim: Uridine diphosphate glucuronosyltransferases (UGTs) are a superfamily of conjugation phase II enzymes and is responsible for catalyzing the glucuronidation of many endobiotic or xenobiotic substrates. The present study aimed to determine allele and genotype frequencies of UGT1A4 c.142T>G, UGT1A6 c.541A>G and UGT1A6 c.19T>G polymorphisms in the healthy Turkish population and also to compare them with different population data. Material and Method: UGT1A4 c.142T>G, UGT1A6 c.541A>G and c.19T>G polymorphisms were determined in DNA samples of 114 healthy Turkish volunteers using polymerase chain reaction and restriction fragment length polymorphism methods. Results: The frequencies of variant alleles were 12.7% for UGT1A4 c.142T>G, 39.9% for UGT1A6 c.541A>G and 44.7% for UGT1A6 c.19T>G. The frequencies of the UGT1A4 and UGT1A6 variant alleles determined were observed to be similar to those of the majority of European populations. However, the UGT1A6 frequencies in the Turk population differed significantly from those reported specifically for the Thai and East Asian populations. Conclusion: This study introduces the frequencies of UGT1A4 and UGT1A6 polymorphisms in the Turkish population. To our knowledge, this is the first report that investigated the frequencies of UGT1A6 c.541A>G and c.19T>G polymorphisms in a healthy Turkish population. A study of the UGTA1A4*3 polymorphism was found in Turkish epilepsy patients in the literature search, but not in healthy individuals. Therefore, it can be stated that this study is also the first report investigating the UGT1A4*3 polymorphism in the healthy Turkish individuals. This study could ensure clinically beneficial information about drug metabolism by UGT1A4 and UGT1A6 in Turkish population.